Santalcamphor is a rare eremophilane sesquiterpene ketone most closely associated in this archive with Buddha wood and related Eremophila mitchellii timber profiles. Compared with common terpenes, its evidence base is narrow but unusually specific: public chemistry references support its identity, and the literature ties it directly to authenticated Eremophila eremophilane fractions and to a small cytotoxicity-oriented preclinical record. That makes santalcamphor best framed as a distinctive Australia-linked marker constituent with experimental bioactivity signals, not as an established human-use active.
Chemical identity and composition
PubChem and NIST support santalcamphor as C15H24O2, with NIST listing CAS 66884-74-0. The clearest accessible constituent context comes from Eremophila mitchellii wood oil, where the archive's Buddha Wood records place santalcamphor at 15.81% in a recent batch report and 29.1% in an aged Buddha wood profile anchored to published chemistry.
Aroma and practical use
- Use the recorded woody, earthy, soft, sesquiterpenic descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
purification and cytotoxicity in eremophila
A Phytochemistry abstract reported purification and NMR elucidation of santalcamphor from Eremophila mitchellii and stated that the essential oils together with the purified eremophilanes exhibited cytotoxicity against P388D(1) mouse lymphoblast cells in vitro.
Measured: constituent identification and in-vitro cytotoxicity
This experimental finding does not establish benefit, dose or safety in people using this blend.
authenticated occurrence in australian semi desert volatiles
A 2021 full-text review of Australia's semi-desert volatiles listed santalcamphor among the rare Eremophila components authenticated by matching 1H or 13C NMR spectra to published values.
Measured: confirmed constituent identity in Eremophila chemistry
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA limit, dermal restriction, or human safety study was verified in the reviewed public sources for isolated santalcamphor.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Because santalcamphor literature is concentrated in analytical chemistry and early preclinical work, archive copy should keep any bioactivity framing narrow and clearly non-medical.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (7)
- No human clinical literature for isolated santalcamphor was verified in this pass.
- Accessible mechanism-specific papers for isolated santalcamphor were not located beyond broader eremophilane chemistry and cytotoxicity context.
- Constituent-specific sensitization, dermal-limit, and repeated-dose safety data were not located in the reviewed public sources.
- No IFRA, RIFM, Tisserand & Young, or EU Annex III dermal limit or sensitization determination was found for santalcamphor as of 2026-07-13 verification pass; the previous dermal_limit_pct value of 10 had no locatable citation and was corrected to null.
- Second-pass 2026-07-13 web search targeting CAS 66884-74-0 directly (RIFM fragrancematerialsafetyresource.elsevier.com lookup by CAS, IFRA 50th Amendment standards PDF) again returned no santalcamphor-specific assessment; only unrelated RIFM PDFs (santalol, citral, coumarin) surfaced. Negative result confirmed via a distinct search angle from the first pass; no further correction made.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.